HGHana Golding

Hana Golding

*This is an algorithmically generated author record based on publicly available information.

Hana Golding has a total of 60 co-authors. Here are the top co-authors by number of shared publications:

  • Lisa R. King

    ‡Division of Viral Products and ∥Core Facility, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, ¶Laboratory of Parasitic Diseases and ¶¶Laboratory of Malaria and Vector Research, NIAID, National Institutes of Health, Bethesda, Maryland 20892, **Division of Molecular Neurobiology, BMC-A12, SE-221 84 Lund, Sweden, and §§Oregon Health and Sciences University, Portland, Oregon 97239

    5 shared publications
  • Jody Manischewitz

    From the Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration, Bethesda, MD; the Laboratory of Parasitic Diseases and the Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD; and the Salk Institute for Biological Studies, Infectious Diseases Laboratory, La Jolla, CA

    4 shared publications
  • Marina Zaitseva

    Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, 8800 Rockville Pike, Bethesda, MD 20892, USA

    3 shared publications
  • Surender Khurana

    Division of Viral Products, Center for Biologics Evaluation and Research (CBER), FDA, Bethesda, MD 20892, USA

    3 shared publications
  • Alan Sher

    ‡Division of Viral Products and ∥Core Facility, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, ¶Laboratory of Parasitic Diseases and ¶¶Laboratory of Malaria and Vector Research, NIAID, National Institutes of Health, Bethesda, Maryland 20892, **Division of Molecular Neurobiology, BMC-A12, SE-221 84 Lund, Sweden, and §§Oregon Health and Sciences University, Portland, Oregon 97239

    2 shared publications
  • Dimiter S. Dimitrov

    Center for Cancer Research, NCI-Frederick, National Institutes of Health, Frederick, Maryland 21702

    2 shared publications

Latest Publications

  • Open Access

    Human Immunodeficiency Virus (HIV) Vaccine Trials: a Novel Assay for Differential Diagnosis of HIV Infections in the Face of Vaccine-Generated Antibodies

    by Surender Khurana, James Needham, Bonnie Mathieson, Isaac R. Rodriguez-Chavez, Andrew T. Catanzaro, Robert T. Bailer, Jerome Kim, Vicky Polonis, David A. Cooper, Jan Guerin, et al.

    All current human immunodeficiency virus (HIV) vaccine candidates contain multiple viral components and elicit antibodies that react positively in licensed HIV diagnostic tests, which contain similar viral products. Thus, vaccine trial participants could be falsely diagnosed as infected with HIV. Additionally, uninfected, seropositive vaccinees may encounter long-term social and economic harms. Moreover, this also interferes with early detection of true HIV infections during preventive HIV vaccine trials. An HIV-seropositive test result among uninfected vaccine trial participants is a major public health concern for volunteers who want to participate in future HIV vaccine trials. Based on the increased number of HIV vaccines being tested globally, it is essential to differentiate vaccine- from virus-induced antibodies. Using a whole-HIV-genome phage display library, we identified conserved sequences in Env-gp41 and Gag-p6 which are recognized soon after infection, do not contain protective epitopes, and are not part of most current HIV vaccines. We established a new HIV serodetection assay based on these peptides. To date, this assay, termed HIV-SELECTEST, demonstrates >99% specificity and sensitivity. Importantly, in testing of plasma samples from multiple HIV vaccine trials, uninfected trial participants scored negative, while all intercurrent infections were detected within 1 to 3 months of HIV infection. The new HIV-SELECTEST is a simple but robust diagnostic tool for easy implementation in HIV vaccine trials and blood banks worldwide.


  • Open Access

    CCR5 N-terminal Region Plays a Critical Role in HIV-1 Inhibition by Toxoplasma gondii-derived Cyclophilin-18

    by Hana Golding, Surender Khurana, Felix Yarovinsky, Lisa R. King, Galina Abdoulaeva, Liselotte Antonsson, Christer Owman, Emily J. Platt, David Kabat, John F. Andersen, et al.


  • Open Access

    Identification of a Linear Peptide Recognized by Monoclonal Antibody 2D7 Capable of Generating CCR5-Specific Antibodies with Human Immunodeficiency Virus-Neutralizing Activity

    by Surender Khurana, Michael Kennedy, Lisa R. King, Hana Golding

    CCR5 is the major coreceptor for human immunodeficiency virus (HIV) infection. The murine monoclonal antibody (MAb) 2D7, which recognizes a conformation-dependent epitope in the second extracellular loop of CCR5, is one of the most potent inhibitors of R5 virus cell entry. However, attempts to humanize 2D7 for in vivo human use have been unsuccessful so far. A filamentous phage library expressing random peptides was used to identify a peptide mimitope that is recognized by MAb 2D7. A synthetic peptide containing this sequence (2D7-2SK) bound to MAb 2D7 with high affinity and reversed its HIV type 1 (HIV-1) fusion inhibitory activity. The peptide contains sequence homologies to two distal regions of the second extracellular loop of human CCR5, both of which are required for MAb 2D7 binding. Rabbit anti-2D7-mimitope antibodies competed with MAb 2D7 for binding to the 2D7-2SK peptide in Biacore biosensor testing. Importantly, the rabbit anti-2D7-2SK antibodies bound to CCR5 on cells and specifically inhibited R5 (but not X4) envelope-mediated syncytium formation. These antibodies also neutralized infection of human peripheral blood mononuclear cells with R5 HIV isolates comparably to MAb 2D7. In summary, we have identified a novel peptide that closely mimics the MAb 2D7 epitope on CCR5. This peptide could be included as a potential vaccine candidate or to isolate 2D7-like human antibodies as entry inhibitors for R5 viruses.


  • Systemic and mucosal immunity in rhesus macaques immunized with HIV‐1 peptide and gp120 conjugated to Brucella abortus

    by Nancy Eller, Hana Golding, Satoshi Inoue, Paul Beining, John Inman, Natasha Matthews, Dorothy E. Scott, Basil Golding

    HIV vaccine testing in primates is an important method for determining the possibility of vaccine benefit in humans. Goals of HIV‐1 vaccination include establishing neutralizing antibodies and a strong CD8+ T‐cell response. We tested a novel vaccine conjugate for its ability to elicit relevant immune responses to HIV proteins and peptides in rhesus macaques. A neutralizing epitope, V3 loop peptide from HIV‐1 envelope, was coupled to heat‐inactivated Brucella abortus (V3‐HKBA). Rhesus macaques were immunized with this conjugate in the anterior thigh. After two immunizations V3‐specific antibodies were found in the sera and at mucosal sites. Neutralizing activity of these antibodies was demonstrated by syncytia inhibition assays. Cellular immune recall responses were demonstrated by antigen‐specific induction of interferon‐gamma and Regulation on Activation Noraml T Cell Expressed and Secreted (RANTES) secretion in vitro. These results confirm and extend preliminary studies in mice that suggest HKBA is an effective carrier that promotes neutralizing antibody secretion at relevant mucosal sites, as well as cellular immune responses that are correlated with viral protection.


  • Inhibition of HIV-1 infection by a CCR5-binding cyclophilin from Toxoplasma gondii

    by Hana Golding, Julio Aliberti, Lisa R. King, Jody Manischewitz, John Andersen, Jesus Valenzuela, Nathaniel R. Landau, Alan Sher

    The activation of murine dendritic cells by Toxoplasma gondii has recently been shown to depend on a parasite protein that signals through the chemokine receptor CCR5. Here we demonstrate that this molecule, cyclophilin-18 (C-18), is an inhibitor of HIV-1 cell fusion and infection with cell-free virus. T gondii C-18 efficiently blocked syncytium formation between human T cells and effector cells expressing R5 but not X4 envelopes. Neither human nor Plasmodium falciparum cyclophilins possess such inhibitory activity. Importantly, C-18 protected peripheral blood leukocytes from infection with multiple HIV-1 R5 primary isolates from several clades. C-18 bound directly to human CCR5, and this interaction was partially competed by the β-chemokine macrophage inflammatory protein 1β (MIP-1β) and by HIV-1 R5 gp120. In contrast to several other antagonists of HIV coreceptor function, C-18 mediated inhibition did not induce β-chemokines or cause CCR5 downmodulation, suggesting direct blocking of envelope binding to the receptor. These data support the further development of C-18 derivatives as HIV-1 inhibitors for preventing HIV-1 transmission and for postexposure prophylaxis.


  • Open Access

    Development of a Novel Vaccinia‐Neutralization Assay Based on Reporter‐Gene Expression

    by Jody Manischewitz, Lisa R. King, Nicole A. Bleckwenn, Joseph Shiloach, Rolf Taffs, Michael Merchlinsky, Nancy Eller, Malgorzata G. Mikolajczyk, David J. Clanton, Thomas Monath, et al.

    In anticipation of large-scale smallpox vaccination, clinical trials of new vaccine candidates with improved safety profiles, and new vaccinia immune


  • CXCR4 heterogeneity in primary cells: possible role of ubiquitination

    by Cheryl K Lapham, Tatiana Romantseva, Emmanuel Petricoin, Lisa R King, Jody Manischewitz, Marina B Zaitseva, Hana Golding

    The chemokine receptor CXCR4 is a primary coreceptor for the HIV-1 virus. The predicted molecular weight (MW) of glycosylated CXCR4 is 45–47 kDa. However, immunoblots of whole cell lysates from human lymphocytes, monocytes, macrophages, and the Jurkat T-lymphocyte line revealed multiple MW isoforms of CXCR4. Three of the bands could be precipitated by anti-CXCR4 monoclonal antibodies (101 and 47 kDa) or coprecipitated with CD4 (62 kDa). Expression of these isoforms was enhanced by infection with a recombinant vaccinia virus encoding CXCR4. In immunoblots of two-dimensional gels, antiubiquitin antibodies reacted with the 62-kDa CXCR4 species from monocytes subsequent to coprecipitation with anti-CD4 antibodies. Culturing of monocytes and lymphocytes with lactacystin enhanced the amount of the 101-kDa CXCR4 isoform in immunoblots by three- to sevenfold. In lymphocytes, lactacystin also increased cell-surface expression of CXCR4, which correlated with enhanced fusion with HIV-1 envelope-expressing cells. Similar increases in the intensity of the 101-kDa isoform were seen after treatment with the lysosomal inhibitors monensin and ammonium chloride. Antiubiquitin antibodies reacted with multiple proteins above 62 kDa, which were precipitated with anti-CXCR4 antibodies. Our data indicate that ubiquitination may contribute to CXCR4 heterogeneity and suggest roles for proteasomes and lysosomes in the constitutive turnover of CXCR4 in primary human cells.


  • Open Access

    Dissection of Human Immunodeficiency Virus Type 1 Entry with Neutralizing Antibodies to gp41 Fusion Intermediates

    by Hana Golding, Marina Zaitseva, Eve de Rosny, Lisa R. King, Jody Manischewitz, Igor Sidorov, Miroslaw K. Gorny, Susan Zolla-Pazner, Dimiter S. Dimitrov, Carol D. Weiss

    Human immunodeficiency virus type 1 (HIV-1) entry requires conformational changes in the transmembrane subunit (gp41) of the envelope glycoprotein (Env) involving transient fusion intermediates that contain exposed coiled-coil (prehairpin) and six-helix bundle structures. We investigated the HIV-1 entry mechanism and the potential of antibodies targeting fusion intermediates to block Env-mediated membrane fusion. Suboptimal temperature (31.5°C) was used to prolong fusion intermediates as monitored by confocal microscopy. After transfer to 37°C, these fusion intermediates progressed to syncytium formation with enhanced kinetics compared with effector-target (E/T) cell mixtures that were incubated only at 37°C. gp41 peptides DP-178, DP-107, and IQN17 blocked fusion more efficiently (5- to 10-fold-lower 50% inhibitory dose values) when added to E/T cells at the suboptimal temperature prior to transfer to 37°C. Rabbit antibodies against peptides modeling the N-heptad repeat or the six-helix bundle of gp41 blocked fusion and viral infection at 37°C only if preincubated with E/T cells at the suboptimal temperature. Similar fusion inhibition was observed with human six-helix bundle-specific monoclonal antibodies. Our data demonstrate that antibodies targeting gp41 fusion intermediates are able to bind to gp41 and arrest fusion. They also indicate that six-helix bundles can form prior to fusion and that the lag time before fusion occurs may include the time needed to accumulate preformed six-helix bundles at the fusion site.


  • Increased Association of Glycoprotein 120-CD4 with HIV Type 1 Coreceptors in the Presence of Complex-Enhanced Anti-CD4 Monoclonal Antibodies

    by Hana Golding, Jun Ouyang, Marina Zaitseva, Christopher C. Broder, Dimiter S. Dimitrov, Cheryl Lapham

    CD4-specific monoclonal antibodies (CG1, CG7, and CG8), which bind with a 5- to 10-fold higher avidity to preformed CD4-gp120 complexes than to CD4, were previously shown to recognize newly identified conformational epitopes in the D1-CDR3 region of CD4. In the current study, these and other complex-enhanced MAbs were tested in three separate assays of HIV-1 coreceptor (CXCR4/CCR5) recruitment. In these assays, the CD4-specific MAbs CG1, -7, and-8 stabilized the association of coreceptor, gp120, and CD4 in trimolecular complexes. In contrast, the gp120-specific, complex-enhanced MAbs 48d and 17b were inhibitory. These data suggest that conformational changes in the CDR3 region of CD4-D1, induced by gp120 binding, may be involved in coreceptor association and thus play a positive role in the HIV-1 cell fusion process.